Clinerion's Patient Recruitment System Makes U.S. Debut
Clinerion will present its Patient Recruitment System (PRS), which allows real-time patient search for clinical trials via direct query of electronic health records.
Basel, Switzerland-based technology services company Clinerion will introduce its clinical research solutions in North America at SCOPE, the Summit for Clinical Ops Executives, and HX360, the Executive Forum for health and technology innovation (part of the HIMMS Health IT Conference).
Clinerion will present its Patient Recruitment System (PRS), which allows real-time patient search for clinical trials via direct query of electronic health records. PRS enables both electronic health record-driven protocol feasibility and patient recruitment. PRS allows trial teams to optimize protocols and to assess the possible number of suitable patients more quickly than manual screening. Patient privacy is maintained and compliant with international standards such as HIPAA, and the FDA, as patient data is never removed from the hospital premises and are de-identified before query.
Read the full release.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
